GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » EPS without NRI

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) EPS without NRI : $-0.11 (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings EPS without NRI?

Parnell Pharmaceuticals Holdings's earnings per share without non-recurring items for the six months ended in Dec. 2018 was $-0.11. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Parnell Pharmaceuticals Holdings's EPS without NRI or its related term are showing as below:

PARNF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.35
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Parnell Pharmaceuticals Holdings's EPS (Diluted) for the six months ended in Dec. 2018 was $0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2018 was $0.01.

Parnell Pharmaceuticals Holdings's EPS (Basic) for the six months ended in Dec. 2018 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2018 was $0.01.


Parnell Pharmaceuticals Holdings EPS without NRI Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings EPS without NRI Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
EPS without NRI
Get a 7-Day Free Trial -1.93 -0.75 -1.01 -0.98 -0.11

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
EPS without NRI Get a 7-Day Free Trial -1.93 -0.75 -1.01 -0.98 -0.11

Competitive Comparison of Parnell Pharmaceuticals Holdings's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's PE Ratio without NRI falls into.



Parnell Pharmaceuticals Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Parnell Pharmaceuticals Holdings EPS without NRI Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.